Survival Benefit of Concurrent Chemoradiation Therapy for Unresected Glioblastoma Multiforme in the Temozolomide Era

PTV with the 90% isodose volume. Acute side effects were headache in 32%, nausea in 15%, conjunctivitis in 5%, keratitis in 5%, and optic papillitis in 2%. Fifteen percent of patients required corticosteroids during SRT. Chronic toxicities included retinopathy (7%), pituitary dysfunction (7%), chronic ocular pain (2%), and cataracts (2%). Visual acuity was stable in 65%, improved in 28%, and decreased in 8% of patients. Visual fields were stable in 71%, improved in 21% and reduced in 9% of patients. Actuarial 5-year local control rates were 100% for primary ONSM and 88% for secondary ONSM. Actuarial 5-year visual preservation rates were 100% for primary ONSM and 86% for secondary ONSM. Two patients with secondary ONSM experienced disease progression: one was salvaged with surgery while the other died of other causes before treatment for ONSM was required. Conclusion: SRT for primary and secondary ONSM was well tolerated and provided excellent local control and vision preservation at our institution. Longer follow-up is required to determine the risk of late ocular and pituitary sequelae. Author Disclosure: S. Hamilton: None. A. Nichol: None. F. Hsu: None. P. Truong: None. P. Dolman: None. A.K. Cheung: None. M. McKenzie: None. R. Ma: None.